Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens

Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company.

This new study aims to further validate the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the prevention and treatment of coccidiosis in broiler chickens. Building upon the positive outcomes of previous trials, this study replicates real-world conditions to ensure the product's effectiveness in commercial poultry production environments.

“We are delighted to support a global leader in animal health as they perform this confirmatory study, which holds potential to accelerate commercialization of our innovative treatment. Coccidiosis costs the poultry industry more than $10 billion annually, and traditional treatments rely heavily on antibiotics and ionophores that have not seen significant innovation in over six decades,” said John Payne, Chairman and CEO of ZIVO Bioscience.

“This 42-day study is a significant step forward in our mission to provide sustainable, antibiotic-free solutions for the poultry industry. Our product represents a groundbreaking alternative designed to boost the immune response of broiler chickens without the adverse effects associated with legacy treatments. We are optimistic the results of this study will further support its market readiness,” he added.

Funded by the major animal health company, the study focuses on the overall health and productivity of the birds under typical industry conditions, and compares administration of ZIVO’s product versus an ionophore-based treatment and versus an ionophore-based treatment combined with ZIVO’s product. The study also compares the benefits of ZIVO’s product combined with coccidiosis vaccine versus administration without the vaccine. Results from the study are expected to be available in September.

About Coccidiosis

Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billioni. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike want to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.

About ZIVO Bioscience

ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit for more information.

Forward Looking Statements

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

i Blake, D.P., Knox, J., Dehaeck, B. et al. Re-calculating the cost of coccidiosis in chickens. Vet Res 51, 115 (2020).

ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130

LHA Investor Relations
Tirth T. Patel
(212) 201-6614

Source: ZIVO Bioscience, Inc.